182 related articles for article (PubMed ID: 14871245)
21. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M
Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678
[TBL] [Abstract][Full Text] [Related]
22. A molecular study of the t(4;14) in multiple myeloma.
Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
[TBL] [Abstract][Full Text] [Related]
23. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
24. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.
Chesi M; Bergsagel PL; Kuehl WM
Curr Opin Hematol; 2002 Jul; 9(4):288-93. PubMed ID: 12042702
[TBL] [Abstract][Full Text] [Related]
25. The oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors.
Baumann H; Kunapuli P; Tracy E; Cowell JK
J Biol Chem; 2003 May; 278(18):16198-208. PubMed ID: 12594223
[TBL] [Abstract][Full Text] [Related]
26. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling.
Ben-Zvi T; Yayon A; Gertler A; Monsonego-Ornan E
J Cell Sci; 2006 Jan; 119(Pt 2):380-7. PubMed ID: 16410555
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.
Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Kawano MM
Leuk Lymphoma; 2003 Sep; 44(9):1477-81. PubMed ID: 14565647
[TBL] [Abstract][Full Text] [Related]
28. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
[TBL] [Abstract][Full Text] [Related]
29. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
30. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
Soverini S; Terragna C; Testoni N; Ruggeri D; Tosi P; Zamagni E; Cellini C; Cavo M; Baccarani M; Tura S; Martinelli G
Haematologica; 2002 Oct; 87(10):1036-40. PubMed ID: 12368157
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Chen T; Wang LH; Farrar WL
Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
[TBL] [Abstract][Full Text] [Related]
32. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
[TBL] [Abstract][Full Text] [Related]
33. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.
Li Z; Zhu YX; Plowright EE; Bergsagel PL; Chesi M; Patterson B; Hawley TS; Hawley RG; Stewart AK
Blood; 2001 Apr; 97(8):2413-9. PubMed ID: 11290605
[TBL] [Abstract][Full Text] [Related]
34. Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes.
Gudernova I; Vesela I; Balek L; Buchtova M; Dosedelova H; Kunova M; Pivnicka J; Jelinkova I; Roubalova L; Kozubik A; Krejci P
Hum Mol Genet; 2016 Jan; 25(1):9-23. PubMed ID: 26494904
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
[TBL] [Abstract][Full Text] [Related]
36. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
37. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
[TBL] [Abstract][Full Text] [Related]
38. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
[TBL] [Abstract][Full Text] [Related]
39. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).
Intini D; Baldini L; Fabris S; Lombardi L; Ciceri G; Maiolo AT; Neri A
Br J Haematol; 2001 Aug; 114(2):362-4. PubMed ID: 11529856
[TBL] [Abstract][Full Text] [Related]
40. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]